Clinical trials: Alcoholic Liver Disease
NAFLD, Pre-diabetes
Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis
Oxidative stress is produced by imbalance between reactive oxygen species and antioxidant systems. This state is frequently associated with chronic diseases like obesity, insulin resistance, metabolic syndrome and hepatic…
- Trial name
- NCT02051842
- Testing
- Metadoxine
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver
Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)
Multicenter, randomized, double-blinded, placebo-controlled clinical trial is focused on novel treatments for non-alcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
- Trial name
- PUVENAFLD (NCT04198805)
- Testing
- Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate]
- Where
- 15 sites in United States
- Volunteers
- 205 people
- Sponsor
- Naga P. Chalasani
Non-alcoholic Fatty Liver Disease
Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease
The study searched for answers to two questions: 1-What are the plasma betatrophin levels in subjects with non-alcoholic fatty liver disease and healthy controls. 2.
- Trial name
- NCT02176811
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
NASH
To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects
First-in-human, single centre, two parts, dose-escalation, parallel-group, safety, tolerability, pharmacokinetic and pharmacodynamic Phase I study.
- Trial name
- NCT06705998
- Testing
- BAR502 single dose, BAR502 multiple doses
- Where
- Switzerland
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
Nonalcoholic Steatohepatitis
Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate whether selonsertib (SEL; GS-4997) can cause fibrosis regression and reduce associated complications in adults with cirrhosis due to NASH.
- Trial name
- STELLAR-4 (NCT03053063)
- Testing
- SEL
- Where
- 283 sites in United States, Australia and 20 more
- Volunteers
- 883 people
- Sponsor
- Gilead Sciences
Nonalcoholic Steatohepatitis
Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis
The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01066364
- Testing
- Colesevelam Hcl
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of California, San Diego
Severe Alcoholic Hepatitis
Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis
After successful screening, first the investigators first treat patients of severe alcoholic hepatitis with steroids for 7 days.
- Trial name
- NCT01820208
- Testing
- G-CSF
- Where
- India
- Volunteers
- 28 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Type 2 Diabetes, Coronary Heart Disease
NMR Metabolomics-Based Risk Assessment and Stratified Digital Health Interventions in Middle-Aged Adults (PREMAP)
PREMAP invites residents of the Eloisa region (South Savo, Finland) turning 45, 50, or 55 years of age in 2026 to undergo a blood-based NMR metabolomics risk assessment for five interlinked cardio-renal-metabolic conditions (type…
- Conditions
- Type 2 Diabetes, Coronary Heart Disease, Myocardial Infarction, Cerebrovascular Disease
- Trial name
- PREMAP (NCT07820800)
- Testing
- Digital health interventions
- Where
- Finland
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Metabolic Dysfunction-associated Steatohepatitis
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in…
- Trial name
- NCT07288138
- Testing
- ECC4703, ECC0509
- Where
- 68 sites in United States
- Volunteers
- 160 people
- Sponsor
- Eccogene
NASH (Non-alcoholic Steato-hepatitis)
Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH
This study is to evaluate the effects of Rosiglitazone, insulin sensitizer and alpha-lipoic acid, antioxidant on patients with pathologically proved NASH (non-alcoholic steato-hepatitis).
- Trial name
- NCT01406704
- Testing
- Rosiglitazone, alpha-lipoic acid, Rosiglitazone/alpha-lipoic acid
- Volunteers
- 26 people
- Sponsor
- Seoul St. Mary's Hospital
Non-alcoholic Fatty Liver Disease (NAFLD)
How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?
The hypothesis of this study is that a diet high in sugars will increase abnormalities in blood lipids which are associated with increased cardiovascular disease risk, relative to a diet which is low in sugar.
- Trial name
- CHOT (NCT01790984)
- Testing
- High sugar low starch diet, Low sugar high starch diet
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bruce A. Griffin
Liver Fibrosis Progression in Chronic Liver Disease
LIVER FIBROSIS PREVALENCE IN FRANCE
"Mortality related to complications of cirrhosis, (hemorrhage, hepatic insufficiency and primary liver cancer) is 15,000 per year in France.
- Trial name
- FIBROFRANCE (NCT01927133)
- Where
- France
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
PCOS, NAFLD
Non-alcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome
This study was planned to examine the prevalence of vitamin D insufficiency, insulin resistance, non-alcoholic fatty liver disease (NAFLD), and their relationship with each other and the nutritional status of individuals with…
- Trial name
- NCT05843955
- Testing
- Questionnaire
- Where
- Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Hacettepe University
Fatty Liver
A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this study is to determine whether cysteamine will effectively reduce or reverse the biologic markers of steatohepatitis in patients.
- Trial name
- NCT00799578
- Testing
- Cysteamine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Joel Lavine
Familial Partial Lipodystrophy, Hypertriglyceridemia
Study of Gemcabene in Adults With FPLD
The overall objective of this study is to assess the efficacy and safety of two dosing regimens of gemcabene (300 mg once daily for 24 weeks or 300 mg daily for 12 weeks followed by 600 mg daily for 12 weeks) in up to eight…
- Conditions
- Familial Partial Lipodystrophy, Hypertriglyceridemia, Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT03508687
- Testing
- 300mg Gemcabene, 600mg Gemcabene
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Elif Oral
Type2 Diabetes Mellitus, Nonalcoholic Fatty Liver Disease
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLD
This study focuses on the effects of Henagliflozein on hepatic fat content in patients with type 2 diabetes mellitus (DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- HHTN (NCT06449833)
- Testing
- Henagliflozein and Metformin, Linagliptin and Metformin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhujiang Hospital
Non-alcoholic Steatohepatitis
Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females
Objectives: Primary objective_To evaluate the safety and tolerability after single oral administration of the investigational product (IP), J2H-1702 in healthy female subjects.
- Trial name
- NCT06308874
- Testing
- Amg dose administration group, Bmg dose administration group
- Where
- South Korea
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- J2H Biotech
Nonalcoholic Fatty Liver Disease
Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate relationships between the body's growth hormone "axis" and nonalcoholic fatty liver disease.
- Trial name
- NCT06166797
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Non-Alcoholic Steatohepatitis
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to determine if the investigational treatment volixibat (SHP626) is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT02787304
- Testing
- SHP626
- Where
- 65 sites in United States, Canada and 2 more
- Volunteers
- 197 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Non-alcoholic Fatty Liver Disease, Obesity
Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease
STUDY OBJECTIVE: To explore the clinical efficacy and safety of liraglutide in obesity combined with metabolism-associated fatty liver disease (MAFLD).
- Trial name
- NCT06501326
- Testing
- Liraglutide, Orlistat
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Affiliated Hospital of Nantong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.